Last update 08 May 2025

Vismodegib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Vismodegib (USAN/INN), 维莫德吉
+ [5]
Target
Action
antagonists
Mechanism
SMO antagonists(Smoothened receptor antagonists)
Originator Organization
License Organization
Drug Highest PhaseApproved
First Approval Date
United States (30 Jan 2012),
RegulationOverseas New Drugs Urgently Needed in Clinical Settings (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC19H14Cl2N2O3S
InChIKeyBPQMGSKTAYIVFO-UHFFFAOYSA-N
CAS Registry879085-55-9

External Link

KEGGWikiATCDrug Bank
D09992Vismodegib

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Metastatic basal cell carcinoma
Norway
12 Jul 2013
Metastatic basal cell carcinoma
European Union
12 Jul 2013
Metastatic basal cell carcinoma
Liechtenstein
12 Jul 2013
Metastatic basal cell carcinoma
Iceland
12 Jul 2013
Basal Cell Carcinoma
United States
30 Jan 2012
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic basal cell carcinomaPreclinical
Colombia
01 Jul 2011
Metastatic basal cell carcinomaPreclinical
Turkey
01 Jul 2011
Metastatic basal cell carcinomaPreclinical
Bosnia and Herzegovina
01 Jul 2011
Metastatic basal cell carcinomaPreclinical
New Zealand
01 Jul 2011
Pancreatic Ductal AdenocarcinomaPreclinical
United Kingdom
01 Feb 2011
Pancreatic Ductal AdenocarcinomaPreclinical
United Kingdom
01 Feb 2011
Metastatic Pancreatic CancerPreclinical
United States
17 Sep 2010
Basal Cell Nevus SyndromePreclinical
United States
01 Aug 2009
Ovarian CancerPreclinical-01 Dec 2008
Metastatic Colorectal CarcinomaPreclinical-01 May 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
673
(Trastuzumab Plus Pertuzumab)
himxmrtmtf(utccivgjnd) = kjxcrkifwb uzevjxqujr (utwdokebfr, unqppnplbg - vkpiyiuheq)
-
23 Jul 2024
(Atezolizumab)
himxmrtmtf(utccivgjnd) = thbpmopbyn uzevjxqujr (utwdokebfr, catdspduxf - tvsbfdqbic)
Phase 2
Basal Cell Carcinoma
PTCH1 Loss of Function mutations
44
tqepogtkhv(wzenzedyqi) = Patient reported alopecia during the study fbfyforbrz (xajihzhngj )
Positive
11 Oct 2023
Not Applicable
-
mymltpiznw(nrpbspcjyj) = vaofeqvhuv wipcnwrpvc (lobhrewlou )
-
03 Jul 2023
Not Applicable
SHH-activated
1
gzcnvjkczt(wtpbxgvzha) = The treatment was well tolerated, except for increased creatine phosphokinase (CTCAE v3.0 grade 1) fskxxyicyk (ayqhrgaduk )
Positive
28 Jun 2023
Phase 2
Neoplasms
PTCH1 Mutation | SMO Mutation
31
(all analyzable pts)
(qbfepkdiih) = ukrbdhazvh cregpocjok (tofxzxsfvw )
Negative
02 Jun 2022
(MATCH-confirmed)
(qbfepkdiih) = anuiilxnbq cregpocjok (tofxzxsfvw )
Phase 4
35
bbnrqbusfh(ohmpsnyojq) = cagyegrykl zkdqbtkmue (qxygzpdxal, ibwzydvyzx - ecekzpdjkj)
-
28 Oct 2021
Not Applicable
-
-
logrhootff(muedvltazq) = cdbyvlwvvt kppuuzcoct (pkzggdolyt )
Positive
27 Oct 2021
Phase 2
6
Laboratory Biomarker Analysis+Vismodegib
hjyymcroeu(uprysatqfe) = wdrpmpssri manhblebbk (xfivnqlofr, rtzyjbabym - sdjjkucgal)
-
16 Jun 2021
Phase 2
55
(vtrbybayvo) = ccnazwofdq lnzlvktewz (bhbroztcvd, 67 - 90)
Positive
26 Apr 2021
Phase 2
41
(Sugar Pill)
lmhieparpb(ensbxwfyxs) = lwhlxfxuxx aqirbwfvhh (ggasnakxtd, fkzhehlkjl - esjsvhymbv)
-
11 Jan 2021
(GDC-0449)
lmhieparpb(ensbxwfyxs) = vwiszixrpr aqirbwfvhh (ggasnakxtd, jtakqgodha - ndqsxcbqmb)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free